# Study to Evaluate the Efficacy and Safety of Tenalisib, Given With CHOP Therapy for Front Line Treatment in Patients With PTCL

> **NCT05239910** · PHASE2 · WITHDRAWN · sponsor: **Rhizen Pharmaceuticals SA**

## Conditions studied

- Peripheral T Cell Lymphoma

## Interventions

- **DRUG:** Tenalisib

## Key facts

- **NCT ID:** NCT05239910
- **Lead sponsor:** Rhizen Pharmaceuticals SA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2023-01
- **Primary completion:** 2026-12
- **Final completion:** 2027-05
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Change in development plan
- **Last updated:** 2022-10-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05239910

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05239910, "Study to Evaluate the Efficacy and Safety of Tenalisib, Given With CHOP Therapy for Front Line Treatment in Patients With PTCL". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05239910. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*